

# Reviewing the genetics of heterogeneity in depression: Operationalizations, manifestations, and etiologies

Na Cai<sup>1\*</sup>, Karmel W. Choi<sup>2,3,4,5</sup>, Eiko I. Fried<sup>6</sup>

1. Helmholtz Pioneer Campus, Helmholtz Zentrum München, Neuherberg, Germany
2. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
4. Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
5. Stanley Center for Psychiatric Research, Broad Institute, Boston, MA, USA
6. Department of Psychology, Leiden University, Leiden, Netherlands

Correspondence should be addressed to N.C. ([na.cai@helmholtz-muenchen.de](mailto:na.cai@helmholtz-muenchen.de))

## Abstract

With progress in genome-wide association studies (GWAS) of depression, from identifying zero hits in ~16,000 individuals in 2013 to 223 hits in more than a million individuals in 2020, understanding the genetic architecture of this debilitating condition no longer appears to be an impossible task. The pressing question now is whether recently discovered variants describe the etiology of a single disease entity. There are a myriad of ways to measure and operationalize depression severity, and major depressive disorder (MDD) as defined in the DSM-5 can manifest in more than ten thousand ways based on symptom profiles alone. Variations in developmental timing, comorbidity, and environmental contexts across individuals and samples further add to the heterogeneity. With big data increasingly enabling genomic discovery in psychiatry, it is more timely than ever to explicitly disentangle genetic contributions to what is likely “depressions” rather than depression. Here, we introduce three sources of heterogeneity: operationalization, manifestation, and etiology. We review recent efforts to identify depression subtypes using clinical and data-driven approaches, examine differences in genetic architecture of depression across contexts, and argue that heterogeneity in operationalizations of depression is likely a considerable source of inconsistency. Finally, we offer recommendations and considerations for the field going forward.

## Introduction

Depression is a common, complex, and debilitating condition with a lifetime prevalence of 20% worldwide. Whether it is one unitary construct, or better conceptualized as different and potentially overlapping disorders, has been the subject of vigorous debate over the past decades.

A typical cohort used in genetic studies of depression includes cases with the same diagnosis. However, they often differ in many respects including symptoms, number of episodes, comorbidities, and disease course. This heterogeneity, often hidden and unexamined in GWAS cohorts, has been identified as one of the roadblocks to successfully unraveling the genetic architecture of depression. Initial GWAS efforts were limited by both heterogeneity and low power (1,2). In response, researchers relaxed ascertainment criteria to increase sample sizes (3–7), which likely increased rather than decreased heterogeneity. While this strategy has given us many more GWAS associations over the past 5 years, it has brought into sharper focus issues of measurement and construct heterogeneity (8).

Heterogeneity is irrelevant if depression reflects a single, specific disorder that carves nature at its joints (9), but work in the last decades should have disabused us of this notion. Instead, depression may consist of various subtypes with different underlying biological pathways and environmental contributions. Systematically studying heterogeneity may be crucial for psychiatric genetics moving forward.

## Sources of heterogeneity

We distinguish three sources of heterogeneity that impact genetic studies of depression, shown in **Figure 1**.

First, **operationalization**, including the *construct definition* and its *measurement*. The term “depression” is an umbrella term that has been used to refer to, among others, depressive symptoms as a continuum and clinical depression as a category. The Diagnostic and Statistical Manual of Mental Disorders (DSM–5) (10) offers a formal definition of Major Depressive Disorder (MDD); criteria encompass the presence and duration of key symptoms as well as their cumulative functional impairment. Yet, it was not created with the goal to define a genetically homogeneous phenotype, and have been shaped by the complex history of psychiatry (11,12). Over 280 rating scales have been used to assess depressive symptoms, and common scales only overlap moderately in symptom content (13). Clinical diagnoses and self-report measures have been used to determine depression cases for genetic studies, but rely on different criteria and identify sets of cases that do not fully overlap. Minimal phenotyping approaches may assess a different construct than MDD specified by DSM-5 (8), and referring to all these phenotypes as “major depression” (14) obfuscates important differences. Cultural differences across ethnicity and nationality may also contribute to heterogeneity in measurement (15–17). In the remainder of this review, we refer to “depression” as all operationalizations described above, and MDD as defined by formal diagnostic criteria (e.g., DSM-5).

Second, **manifestations**, which encompass *symptoms, severity, developmental timing, comorbidities, and physiology*. DSM-5 criteria for MDD include diverse symptoms such as low mood,

loss of interest, sleep disturbance, weight changes, psychomotor slowing/agitation, and suicidal ideation. There are up to 10,377 unique ways to meet these diagnostic criteria (18), and cohorts used in genetic studies on MDD likely include cases who differ dramatically in both symptom profiles and severity. Depression is also heterogeneous in other aspects: patients differ in their onset of disease (e.g. adolescence vs. old age), time course (single episode vs multiple episodes), and comorbidities - important dimensions that are often unmeasured and unmodeled in genetic studies. Variations in physiology at the cellular and molecular levels, such as tissue-specific gene expression and neuronal function, may present biological manifestations that underlie the above phenotypic differences.

Third, **etiology**, encompassing the diverse combination of *genetic, environmental, and other* factors leading to one's disease, as well as their interactions. Individuals may have different levels of genetic liability to depression through carrying different risk alleles at genetic loci with effects on the molecular pathways leading to the disease, and they may be exposed to different environmental factors that also add to their disease liability. Further, the effects on depression liability contributed by the risk alleles one carries may change depending on one's physiological (through gene-gene interactions, GXG) and external environments (through gene-environment interactions, GXE).

Progress in the past years stems largely from genetics research studying heterogeneity in depression manifestations and etiology. Below, we review recent efforts to identify depression subtypes using clinical and data-driven approaches, examine differences in genetic architecture of depression across contexts, and discuss their promises and limitations. We argue that heterogeneity in operationalizations of depression cuts across these sections and is likely a considerable source of inconsistency.

### **Using manifestations to understand etiology**

Subtypes of depression have been proposed based on clinical observations and data-driven approaches, and research has largely focused on comparing their genetic architectures and how well they can be predicted with existing polygenic risk scores (PRS).

#### *Theory-driven depression subtypes*

Decades of clinical experience and patients' own accounts have led to clinical subtypes of MDD that are reflected in current DSM-5 specifiers such as atypical, melancholic, and anxious depression. Subtypes have also been proposed based on developmental timing (19,20), treatment resistance (21), and recurrence (22). Such clinical subtypes have been the primary target of genetic studies.

As an example of a symptom-based clinical subtype, atypical depression is primarily characterized by hypersomnia and weight gain, as opposed to depression more typically characterized by insomnia and weight loss. Typical and atypical depression subtypes differ in heritabilities (43% vs. 38%, though with large standard errors), with PRS for other psychiatric traits showing stronger associations with the typical than atypical subtype (23). Conversely, PRS for immune-metabolic traits such as body mass index (BMI) and C-reactive protein are strongly associated with the atypical depression (24), and patients with the atypical subtype were found to carry more genetic risk variants for BMI and C-reactive protein (25). This suggests that atypical MDD may share greater genetic liability with immune-metabolic conditions (26).

In terms of developmental timing, genetic overlap between early and late-onset MDD has been shown to be only moderate (27). PRS from a recent GWAS meta-analysis of depression predicted early-onset MDD better than late-onset (5), and in hospital-treated cases the iPSYCH study, PRS from both bipolar disorder (BIP) and schizophrenia (SCZ) were associated with earlier MDD onset (28,29). Another longitudinal study found that PRS from SCZ and attention deficit hyperactive disorder (ADHD) were associated with early- rather than later-adolescent onset trajectories, suggesting shared genetic contributions for early-onset MDD and other psychiatric and neurodevelopmental conditions (30,31). Different heritabilities have also been found between depression occurring during the perinatal period (e.g., postpartum) and non-perinatal depression (44% vs 32%) (32), with preliminary evidence suggesting stronger associations between PRS of BIP and SCZ with perinatal depression than non-perinatal depression (33,34).

However, research into distinctions between subtypes, whether symptom- or timing-based, relies on data that is often not available. For example, CONVERGE, due to its strict enrollment criteria, is the only genetically informed cohort with a high proportion of cases presenting with melancholic depression (35), which has restricted replication efforts to date. Early GWAS attempts on other clinical features such as episodicity (36) and treatment response (37–39) were limited in power and did not produce positive findings; larger efforts have been recently invigorated (40,41), and we may gain new insights with more data.

#### *Data-driven depression subtypes*

A body of complementary research has emerged to identify depression subtypes using agnostic, data-driven methods. There is over half a century of literature quantifying depression heterogeneity based on symptom data. There are two principled ways, reviewed extensively elsewhere (42–45). First, exploratory and confirmatory factor analyses (EFA, CFA) aim to identify underlying symptom dimensions using the symptom covariance matrix. Studies consistently extract more than two factors, and results largely depend on which symptoms are included (42,46–50). Second, latent class analysis (LCA) aims to determine more homogeneous subgroups of individuals. Across studies, the most consistent finding is that classes are often organized by severity on all symptoms (indicating a continuum rather than separate classes), though specific results are mixed and depend on assessment instruments (42,45,51,52). Overall, measurement heterogeneity across cohorts has made inferences challenging (42). Three further complications are that symptoms are often not fully assessed in controls due to skip-out assessments; analyses are often performed on cases using the very symptoms with which they were selected, incurring collider biases (53); and methods have assumptions, such as conditional independence in LCA, that are not always met (51,54).

Despite these challenges, there are increasing efforts to recover latent dimensions and classes at the genetic level. Building on the identification of three genetic factors reflecting mood, psychomotor/cognitive, and neurovegetative features of MDD using twin modeling (55), a recent EFA on self-reported depression symptoms in UKBiobank obtained similar results and explored associations with depression PRS (56). A new framework, GenomicSEM, generalizes the structural equation modelling (SEM) approach to genetic covariance matrices (57), which can be generated from a joint analysis of GWAS summary statistics of individual depression symptoms, and can be used to test for genetic loadings on latent dimensions of depression.

Other data-driven approaches have been applied to physiological measures to identify etiologically meaningful subtypes. Variations of canonical correlation analysis (CCA) have characterized relationships between depressive symptoms and neuroimaging measures (58), and

hierarchical clustering on resting-state fMRI measures have identified groups of depressed patients and their differential network dysfunctions (59), and machine learning methods have been used to cluster longitudinal responses to antidepressants to identify stable treatment response classes (60). In the future, these data could be integrated with multi-omics data; for example, transcriptome-wide association (TWAS) approaches have begun to identify depression subtypes driven by brain and adipose tissue-specific gene expression (61).

Finally, genetic data has been used directly to identify data-driven subtypes. For example, subsets of MDD cases in UKBiobank with distinct genetic risks for SCZ, high neuroticism, and early age of menopause (62) were identified using BUHMBOX (63), a statistical approach that involves identifying individuals who may carry genetic variants pleiotropic for other traits. Overall, continued efforts to incorporate new types of data and data-driven methods hold great promise for subtype identification and validation.

### Contexts as part of etiology

This section reviews genetic investigations aiming to disentangle etiological heterogeneity across the contexts in which depression manifests. We also discuss challenges to these approaches, including measurement differences and ascertainment biases.

#### *Individual characteristics*

Few genetic studies of depression have been performed in non-European populations, and the extent to which etiological factors for depression differ across populations remains unknown. A recent preprint compared ICD10-based MDD in individuals of African American ancestry (AA, N=59,600) in the Million Veterans Program (MVP) in the USA with a meta-analysis of several depression cohorts of individuals with European ancestry (EUR, N=1.1 million), including MVP (7). While no GWAS hits for MDD were found in AA, likely due to insufficient power, 61% of the GWAS hits from depression in EUR showed the same directions of effect, suggesting a modest overlap in genetic factors leading to depression in people with both ancestries. This echoes results from a study comparing severe recurrent MDD of Han Chinese women (CHN, N=10,640) in the CONVERGE cohort to MDD of EUR in various cohorts from the Psychiatric Genomics Consortium (PGC, EUR N=18,662) (64). Low trans-ancestry genetic correlations were found between MDD in CHN and EUR (57–59) ( $\rho = 0.33$ , 95% CI = 0.27-0.39), and the two GWAS hits from CONVERGE were not replicated due to drastic allele frequency differences (3,5,35).

In the studies discussed above, MDD from AA and CHN was compared with depression measured very differently in EUR. Despite reports of high  $r_G$  between depression assessed in different ways within EUR to justify their use in cross-ancestry comparisons ( $r_G = 0.81-1.07$ )(8,65), it has been demonstrated very clearly that they are distinct phenotypes with different genetic architectures (8). As such, genetic heterogeneity of depression may be overestimated across ancestries due to differences in operationalization. Differences in cultural norms around depression (15,16,66) and study participation (67) can incur ascertainment biases and further affect interpretation of results. Assessing depression across populations requires efforts to understand how this condition manifests differently across settings.

This also applies to heterogeneity across other groups, including those defined by biological sex and socioeconomic status. Differences in MDD genetic architecture between sexes have been shown in both twin studies (68,69) and major GWAS cohorts (70), where heritability of MDD was

found to be higher in females. However, this can be obfuscated by differences in operationalizations and ascertainment strategies between studies. Contrary to previous studies, heritability of depression in females was found to be lower in UKBiobank (8), and it is the only dataset whose PRS for depression in both sexes better predict MDD in males than females in an independent dataset (71). Ascertainment differences are likely to be a major contributor to this discrepancy, and minimizing such differences may unmask patterns across studies.

### *Environments*

Environmental factors contribute a large proportion of variability in depression risk, and stratifying depression cohorts by environmental factors may help identify differential genetic effects between those exposed and not exposed. For example, stratifying by exposure to stressful life events has revealed genetic heterogeneity in severe recurrent MDD from CONVERGE (72–74), with three significant GWAS hits and higher heritability of MDD in the non-exposed group (72), suggesting divergent genetic factors at play among the two groups. However, when MDD and stress exposure were differently defined in the UKBiobank, the opposite finding emerged, with higher heritability of MDD in the exposed group (75). Similar contradictions arose between two studies on interactions between MDD PRS and childhood trauma: in NESDA, MDD PRS was more strongly predictive of depression in trauma-exposed cases (76), while in RADIANT UK, it was more predictive of non-exposed cases (70). Further, a subsequent meta-analysis using cohorts ascertained with a range of strategies identified the third possible outcome – a null-finding (77). This non-replication was attributed to chance findings in the small cohorts used, and to a smaller extent gene-environmental (GE) correlations (77). But a further issue for replication may lie in operationalization differences between studies. Ascertainment biases, as well as heterogeneous measurement of both depression and stress exposures, may lead to differences in unmeasured environmental factors and inconsistencies in both polygenic and environmental contributions to disease liability. GXE effects detected between PRS and environmental contexts could therefore differ accordingly (77,78).

One potential solution is to target efforts at identifying and replicating GXE effects between single variants and environmental exposures. Though efforts to test single-variant GXE have often been thwarted by difficulties in correcting for population structure and other confounding factors, and a general lack of power, recently proposed methods may overcome this. StructLMM extends a linear mixed model approach to test random effects at genetic variants interacting with one or more environmental variables (79), and reverse GWAS (RGWAS) infers subtypes by clustering multiple traits and environmental factors, and tests for genetic heterogeneity between identified subtypes while robustly controlling for confounding factors (73). With larger datasets becoming increasingly available, these methods may start yielding results, even for highly complex traits like depression.

### **Way forward: splitting vs lumping**

As depression may reflect several highly heterogeneous phenotypes, and it is difficult to agree upon a single construct that can be consistently measured, perhaps studying it at the level of a categorical diagnosis or dimensional symptom total score is not the only or best solution. Here, we discuss two alternative ways forward.

First, splitting, i.e. refocusing genetic discovery efforts on more granular phenotypes with higher validity and reliability: individual symptoms (80,81). Recent studies have investigated genetic contributions to individual depressive symptoms (82–85) and how they vary across contexts (86). Analyses have shown that genetic contributions to individual symptoms are not equivalent to those for

MDD (average  $r_G = 0.6$ ), nor to each other ( $r_G$  range 0.6 to 0.9) (56,62). Going beyond symptoms, recent expansions in sequencing and phenotyping technologies such as neuroimaging (87–89) and molecular data (90,91) have enabled genetic analyses on endophenotypes (92). Though genetic contributions to such endophenotypes have not yet been found to have larger individual locus effect sizes (93) or to be any less polygenic (94) than complex diseases, they have been proposed to be more tractable (95). Clustering based on endophenotypes may reveal etiologically meaningful subtypes of depression, and investigating these may allow us to fill in the missing causal links between genetic variants and disease.

Second, lumping, i.e. moving beyond depression alone and embracing transdiagnostic features across related disorders. High comorbidity (96) and pleiotropy (97–99) between psychiatric disorders have motivated attempts to identify common genetic factors and implicated molecular pathways underlying multiple psychiatric disorders (57,100–102). Underlying liability for psychiatric conditions such as the  $p$  factor has been proposed (103), with preliminary evidence of a corresponding genetic basis (104).

Integrating both splitting and lumping, transdiagnostic insights gained from studies of endophenotypes may help us redefine diagnostic boundaries, a goal set out by the Research Domain Criteria (RDoC) 10 years ago (105).

## Conclusions

To summarize, we have identified three overarching sources of heterogeneity: operationalization, manifestations, and etiology. The first pertains to heterogeneity in how we do science, the second and third to heterogeneity of the phenotype itself as well as its causes. Gaining a better understanding of how these three sources impact results in our field is a necessary (though not sufficient) step towards improving diagnostics and targeted treatments. From reviewing the literature, four lessons emerge.

**1) Measure consistently.** Inconsistent findings in subtype identification and their genetic architecture are inevitable if depression is not operationalized consistently. Overall, this calls for harmonizing assessments of depression across studies.


**2) Measure more.** Both theory- and data-driven approaches to disentangle the complex phenotype of depression rely on data, and even the most sophisticated statistical approaches cannot overcome missing input data. One crucial step forward is to assess a broader range of data—including individual depression symptoms and salient clinical characteristics such as age of onset, number of episodes, and recurrence—and utilize them to study depression heterogeneity. Further, new types of data, including data from activity trackers in wearable technologies, text and voice through natural language processing, and longitudinal mood assessment by computerized adaptive screening questionnaires, may be helpful to identifying subtypes for genetic analysis.

**3) Collaborate.** Complex traits like depression cannot be understood in a mono-disciplinary vacuum, because they require, in addition to knowledge of quantitative genetics, a nuanced understanding of the phenotype under investigation. The goal to identify and validate depression subtypes therefore calls for collaborations with clinicians, epidemiologists, sociologists, anthropologists, patients, and others.

**4) Follow through.** To make good on the promise of GWAS to deliver genetic insights that would improve diagnosis, treatment and prevention of depression in individuals with diverse

etiological causes, we need to expand beyond our findings of differences in genetic architecture and PRS associations. Further association testing and fine-mapping using sequencing datasets may help identify individual variants with heterogeneous effects on depression subtypes; integration of multi-omics data may point to the different tissues and biological pathways involved; single cell transcriptomics across developmental time points may lend spatial and temporal resolution; experimental designs in re-differentiated human induced pluripotent stem cells, organoids or model organisms may allow us to validate the biological relevance of effects we find and identify potential targets for drug interventions.

Doing all of this, we may find that depression really consists of an entangled web of partly overlapping biopsychosocial constructs, with overlapping genetic contributions. Perhaps now is the right time for us to take the bold next step and acknowledge the complex reality that the field is searching for the genetic architecture of “depressions” rather than depression. This is a challenge, but simultaneously a great opportunity and offers a clear path forward towards embracing the heterogeneity of depressions in our theories, measures, and methods.



**Figure 1: Sources of heterogeneity in depression.**

This figure shows some of the sources of heterogeneity we discuss in this paper, in terms of operationalization (phenotype, measurement), manifestation (symptoms, time course, group characteristics, comorbidities, endophenotypes) and etiology.

## Acknowledgement



KWC was supported in part by the National Institute of Mental Health (T32MH017119).

### **Conflicts of interest**

The authors declare no conflicts of interest

### **Glossary**

MDD: Major depressive disorder

ADHD: Attention deficit hyperactivity disorder

SCZ: Schizophrenia

BIP: Bipolar disorder

GWAS: Genome-wide association study

PRS: Polygenic risk score(s)

rG: Genetic correlation

RGWAS: Reverse GWAS

EFA: Exploratory factor analysis

CFA: Confirmatory factor analysis

LCA: Latent class analysis

SEM: Structural equation modelling

CCA: Canonical correlation analysis

TWAS: Transcriptome wide association analysis

fMRI: Functional magnetic resonance imaging

AA: African American ancestry

EUR: European ancestry

CHN: Han Chinese ancestry

ICD: International Classification of Diseases

DSM: Diagnostic and Statistical Manual of Mental Disorders

RDoC: Research Domain Criteria

CONVERGE: The China, Oxford and Virginia Commonwealth University Experimental Research on Genetic Epidemiology

PGC: Psychiatric Genomics Consortium

NESDA: The Netherlands Study of Depression and Anxiety

RADIANT UK: A combination of data of UK outpatients from the following studies - Depression Case Control (DeCC), Depression Network (DeNT), and Genome-Based Therapeutic Drugs for Depression (GENDEP)

MVP: The Million Veterans Project

## Reference:

1. Flint J, Kendler KS. The Genetics of Major Depression. *Neuron*. 2014 Feb;81(3):484–503.
2. Levinson DF, Mostafavi S, Milaneschi Y, Rivera M, Ripke S, Wray NR, et al. Genetic studies of major depressive disorder: Why are there no GWAS findings, and what can we do about it? *Biol Psychiatry*. 2014 Oct 1;76(7):510–2.
3. Hyde CL, Nagle MW, Tian C, Chen X, Paciga SA, Wendland JR, et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. *Nat Genet*. 2016 Sep;48(9):1031–6.
4. Howard DM, 23andMe Research Team, Adams MJ, Shirali M, Clarke T-K, Marioni RE, et al. Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. *Nat Commun*. 2018 Dec;9(1):1470.
5. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet*. 2018 May;50(5):668–81.
6. Howard DM, 23andMe Research Team, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Adams MJ, Clarke T-K, Hafferty JD, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat Neurosci*. 2019 Mar;22(3):343–52.
7. Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, et al. GWAS of Depression Phenotypes in the Million Veteran Program and Meta-analysis in More than 1.2 Million Participants Yields 178 Independent Risk Loci [Internet]. *Genetic and Genomic Medicine*; 2020 May [cited 2020 May 25]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.05.18.20100685>
8. Cai N, Revez JA, Adams MJ, Andlauer TFM, Breen G, Byrne EM, et al. Minimal phenotyping yields genome-wide association signals of low specificity for major depression. *Nat Genet*. 2020 Apr;52(4):437–47.
9. Kendler KS, Zachar P, Craver C. What kinds of things are psychiatric disorders? *Psychological Medicine*. 2011 Jun;41(6):1143–50.
10. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders* [Internet]. Fifth Edition. American Psychiatric Association; 2013 [cited 2020 Apr 5]. Available from: <https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596>
11. Kendler KS. The nature of psychiatric disorders. *World Psychiatry*. 2016 Feb;15(1):5–12.
12. Lilienfeld SO. *DSM-5 : Centripetal Scientific and Centrifugal Antiscientific Forces*. *Clin Psychol Sci Pract*. 2014 Sep;21(3):269–79.
13. Fried EI. The 52 symptoms of major depression: Lack of content overlap among seven common depression scales. *Journal of Affective Disorders*. 2017 Jan 15;208:191–7.

14. McIntosh AM, Sullivan PF, Lewis CM. Uncovering the Genetic Architecture of Major Depression. *Neuron*. 2019 Apr 3;102(1):91–103.
15. Kessler RC, Bromet EJ. The Epidemiology of Depression Across Cultures. *Annu Rev Public Health*. 2013 Mar 18;34(1):119–38.
16. Parker G, Gladstone G, Chee KT. Depression in the Planet's Largest Ethnic Group: The Chinese. *AJP*. 2001 Jun;158(6):857–64.
17. Kleinman A. Neurasthenia and depression: A study of somatization and culture in China: Report Number One of the University of Washington ? Hunan Medical College Collaborative Research Project111222. *Cult Med Psych*. 1982 Jun;6(2):117–90.
18. Fried EI, Coomans F, Lorenzo-Luaces L. The 341 737 ways of qualifying for the melancholic specifier. *The Lancet Psychiatry*. 2020 Jun;7(6):479–80.
19. Power RA, Tansey KE, Buttenschøn HN, Cohen-Woods S, Bigdeli T, Hall LS, et al. Genome-wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. *Biol Psychiatry*. 2017 Feb 15;81(4):325–35.
20. Harrington R, Rutter M, Fombonne E. Developmental pathways in depression: Multiple meanings, antecedents, and endpoints. *Dev Psychopathol*. 1996;8(4):601–16.
21. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? *Biological Psychiatry*. 2003 Apr;53(8):640–8.
22. Merikangas KR, Wicki W, Angst J. Heterogeneity of Depression: Classification of Depressive Subtypes by Longitudinal Course. *The British Journal of Psychiatry*. 1994 Mar;164(3):342–8.
23. Milaneschi Y, Lamers F, Peyrot WJ, Abdellaoui A, Willemsen G, Hottenga J-J, et al. Polygenic dissection of major depression clinical heterogeneity. *Mol Psychiatry*. 2016 Apr;21(4):516–22.
24. Badini I, Coleman JR, Hagenaars SP, Hotopf M, Breen G, Lewis CM, et al. Atypical depression shares genetic predisposition with immuno-metabolic traits: a population-based study [Internet]. *Genetic and Genomic Medicine*; 2020 Feb [cited 2020 May 21]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.02.18.20024091>
25. Milaneschi Y, Lamers F, Peyrot WJ, Baune BT, Breen G, Dehghan A, et al. Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. *JAMA Psychiatry*. 2017 Dec 1;74(12):1214.
26. Milaneschi Y, Lamers F, Berk M, Penninx BWJH. Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. *Biological Psychiatry*. 2020 Jan;S0006322320300482.
27. Weissman MM. Onset of Major Depression in Early Adulthood: Increased Familial Loading and Specificity. *Arch Gen Psychiatry*. 1984 Dec 1;41(12):1136.

28. Musliner KL, Mortensen PB, McGrath JJ, Suppli NP, Hougaard DM, Bybjerg-Grauholm J, et al. Association of Polygenic Liabilities for Major Depression, Bipolar Disorder, and Schizophrenia With Risk for Depression in the Danish Population. *JAMA Psychiatry*. 2019 May 1;76(5):516–25.
29. Verduijn J, Milaneschi Y, Peyrot WJ, Hottenga JJ, Abdellaoui A, Geus EJC de, et al. Using Clinical Characteristics to Identify Which Patients With Major Depressive Disorder Have a Higher Genetic Load for Three Psychiatric Disorders. *Biological Psychiatry*. 2017 Feb 15;81(4):316–24.
30. Rice F, Riglin L, Thapar AK, Heron J, Anney R, O'Donovan MC, et al. Characterizing Developmental Trajectories and the Role of Neuropsychiatric Genetic Risk Variants in Early-Onset Depression. *JAMA Psychiatry*. 2019 Mar 1;76(3):306.
31. Kwong ASF, López-López JA, Hammerton G, Manley D, Timpson NJ, Leckie G, et al. Genetic and Environmental Risk Factors Associated With Trajectories of Depression Symptoms From Adolescence to Young Adulthood. *JAMA Netw Open*. 2019 Jun 28;2(6):e196587.
32. Viktorin A, Meltzer-Brody S, Kuja-Halkola R, Sullivan PF, Landén M, Lichtenstein P, et al. Heritability of Perinatal Depression and Genetic Overlap With Nonperinatal Depression. *AJP*. 2016 Feb;173(2):158–65.
33. Byrne EM, Psychiatric Genomic Consortium Major Depressive Disorder Working Group, Carrillo-Roa T, Penninx BWJH, Sallis HM, Viktorin A, et al. Applying polygenic risk scores to postpartum depression. *Arch Womens Ment Health*. 2014 Dec;17(6):519–28.
34. Bauer AE, Liu X, Byrne EM, Sullivan PF, Wray NR, Agerbo E, et al. Genetic risk scores for major psychiatric disorders and the risk of postpartum psychiatric disorders. *Transl Psychiatry*. 2019 Dec;9(1):288.
35. CONVERGE consortium. Sparse whole-genome sequencing identifies two loci for major depressive disorder. *Nature*. 2015 Jul;523(7562):588–91.
36. Ferentinos P, Rivera M, Ising M, Spain SL, Cohen-Woods S, Butler AW, et al. Investigating the genetic variation underlying episodicity in major depressive disorder: Suggestive evidence for a bipolar contribution. *Journal of Affective Disorders*. 2014 Feb 1;155:81–9.
37. Hunter AM, Leuchter AF, Power RA, Muthén B, McGrath PJ, Lewis CM, et al. A genome-wide association study of a sustained pattern of antidepressant response. *Journal of Psychiatric Research*. 2013 Sep 1;47(9):1157–65.
38. Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D, et al. Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. *PLOS Medicine*. 2012 Oct 16;9(10):e1001326.
39. GENDEP Investigators, MARS Investigators, STAR\*D Investigators, Uher R, Tansey KE, Henigsberg N, et al. Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. *AJP*. 2013 Feb;170(2):207–17.

40. Fabbri C, Kasper S, Kautzky A, Zohar J, Souery D, Montgomery S, et al. A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. *Transl Psychiatry*. 2020 Dec;10(1):50.
41. Wigmore EM, Hafferty JD, Hall LS, Howard DM, Clarke T-K, Fabbri C, et al. Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP. *Pharmacogenomics J*. 2020 Apr;20(2):329–41.
42. van Loo HM, de Jonge P, Romeijn J-W, Kessler RC, Schoevers RA. Data-driven subtypes of major depressive disorder: a systematic review. *BMC Medicine*. 2012 Dec 4;10(1):156.
43. Marquand AF, Wolfers T, Mennes M, Buitelaar J, Beckmann CF. Beyond Lumping and Splitting: A Review of Computational Approaches for Stratifying Psychiatric Disorders. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*. 2016 Sep 1;1(5):433–47.
44. Beijers L, Wardenaar KJ, van Loo HM, Schoevers RA. Data-driven biological subtypes of depression: systematic review of biological approaches to depression subtyping. *Molecular Psychiatry*. 2019 Jun;24(6):888–900.
45. Ulbricht CM, Chrysanthopoulou SA, Levin L, Lapane KL. The Use of Latent Class Analysis for Identifying Subtypes of Depression: A Systematic Review. *Psychiatry Res*. 2018 Aug;266:228–46.
46. Shafer AB. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. *Journal of Clinical Psychology*. 2006;62(1):123–46.
47. Romera I, Delgado-Cohen H, Perez T, Caballero L, Gilaberte I. Factor analysis of the Zung self-rating depression scale in a large sample of patients with major depressive disorder in primary care. *BMC Psychiatry*. 2008 Dec;8(1):4.
48. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A, et al. Measuring depression: comparison and integration of three scales in the GENDEP study. *Psychological Medicine*. 2008 Feb;38(2):289–300.
49. Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Factor structure and dimensionality of the two depression scales in STAR\*D using level 1 datasets. *Journal of Affective Disorders*. 2011 Aug;132(3):396–400.
50. Li Y, Aggen S, Shi S, Gao J, Li Y, Tao M, et al. The structure of the symptoms of major depression: exploratory and confirmatory factor analysis in depressed Han Chinese women. *Psychol Med*. 2014 May;44(7):1391–401.
51. van Loo HM, Wanders RBK, Wardenaar KJ, Fried EI. Problems with latent class analysis to detect data-driven subtypes of depression. *Mol Psychiatry*. 2018 Mar;23(3):495–6.
52. Fried EI, van Borkulo CD, Epskamp S, Schoevers RA, Tuerlinckx F, Borsboom D. Measuring depression over time . . . Or not? Lack of unidimensionality and longitudinal measurement invariance in four common rating scales of depression. *Psychological Assessment*. 2016 Nov;28(11):1354–67.

53. Munafò MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope: when selection bias can substantially influence observed associations. *International Journal of Epidemiology*. 2018 Feb 1;47(1):226–35.
54. Borsboom D, Rhemtulla M, Cramer AOJ, van der Maas HLJ, Scheffer M, Dolan CV. Kinds *versus* continua: a review of psychometric approaches to uncover the structure of psychiatric constructs. *Psychol Med*. 2016 Jun;46(8):1567–79.
55. Kendler KS, Aggen SH, Neale MC. Evidence for Multiple Genetic Factors Underlying DSM-IV Criteria for Major Depression. *JAMA Psychiatry*. 2013 Jun 1;70(6):599–607.
56. Jermy BS, Hagenaars SP, Glanville KP, Coleman JR, Howard DM, Breen G, et al. Using Major Depression Polygenic Risk Scores to Explore the Depressive Symptom Continuum. *bioRxiv*. 2020 Feb 26;2020.02.25.962704.
57. Grotzinger AD, Rhemtulla M, de Vlaming R, Ritchie SJ, Mallard TT, Hill WD, et al. Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. *Nature Human Behaviour*. 2019 May;3(5):513–25.
58. Ing A, IMAGEN Consortium, Sämann PG, Chu C, Tay N, Biondo F, et al. Identification of neurobehavioural symptom groups based on shared brain mechanisms. *Nat Hum Behav*. 2019 Dec;3(12):1306–18.
59. Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. *Nature Medicine*. 2017 Jan;23(1):28–38.
60. Paul R, Andlauer TillFM, Czamara D, Hoehn D, Lucae S, Pütz B, et al. Treatment response classes in major depressive disorder identified by model-based clustering and validated by clinical prediction models. *Transl Psychiatry*. 2019 Dec;9(1):187.
61. Majumdar A, Giambartolomei C, Cai N, Freund MK, Haldar T, Schwarz T, et al. Leveraging eQTLs to identify individual-level tissue of interest for a complex trait [Internet]. *Genetics*; 2019 Jun [cited 2020 May 28]. Available from: <http://biorxiv.org/lookup/doi/10.1101/674226>
62. Howard DM, Folkersen L, Coleman JRI, Adams MJ, Glanville K, Werge T, et al. Genetic stratification of depression in UK Biobank. *Transl Psychiatry*. 2020 Dec;10(1):163.
63. Han B, Eskin E. Random-Effects Model Aimed at Discovering Associations in Meta-Analysis of Genome-wide Association Studies. *The American Journal of Human Genetics*. 2011 May;88(5):586–98.
64. Bigdeli TB, on behalf of the CONVERGE consortium and Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Ripke S, Peterson RE, Trzaskowski M, Bacanu S-A, et al. Genetic effects influencing risk for major depressive disorder in China and Europe. *Transl Psychiatry*. 2017 Mar;7(3):e1074–e1074.
65. Weissbrod O, Flint J, Rosset S. Estimating SNP-Based Heritability and Genetic Correlation in Case-Control Studies Directly and with Summary Statistics. *The American Journal of Human Genetics*. 2018 Jul 5;103(1):89–99.

66. Liao S-C, Chen WJ, Lee M-B, Lung F-W, Lai T-J, Liu C-Y, et al. Low prevalence of major depressive disorder in Taiwanese adults: possible explanations and implications. *Psychol Med*. 2012 Jun;42(6):1227–37.
67. Adams MJ, Hill WD, Howard DM, Dashti HS, Davis KAS, Campbell A, et al. Factors associated with sharing e-mail information and mental health survey participation in large population cohorts. *International Journal of Epidemiology*. 2019 Jul 1;dyz134.
68. Kendler KS. A Population-Based Twin Study of Major Depression in Women: The Impact of Varying Definitions of Illness. *Arch Gen Psychiatry*. 1992 Apr 1;49(4):257.
69. Bierut LJ. Major Depressive Disorder in a Community-Based Twin Sample: Are There Different Genetic and Environmental Contributions for Men and Women? *Archives of General Psychiatry*. 1999 Jun 1;56(6):557–63.
70. Trzaskowski M, Mehta D, Peyrot WJ, Hawkes D, Davies D, Howard DM, et al. Quantifying between-cohort and between-sex genetic heterogeneity in major depressive disorder. *Am J Med Genet*. 2019 Sep;180(6):439–47.
71. Hall LS, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Adams MJ, Arnau-Soler A, Clarke T-K, Howard DM, et al. Genome-wide meta-analyses of stratified depression in Generation Scotland and UK Biobank. *Transl Psychiatry*. 2018 Dec;8(1):9.
72. Peterson RE, Cai N, Dahl AW, Bigdeli TB, Edwards AC, Webb BT, et al. Molecular Genetic Analysis Subdivided by Adversity Exposure Suggests Etiologic Heterogeneity in Major Depression. *AJP*. 2018 Jun;175(6):545–54.
73. Dahl A, Cai N, Ko A, Laakso M, Pajukanta P, Flint J, et al. Reverse GWAS: Using genetics to identify and model phenotypic subtypes. *PLOS Genetics*. 2019 Apr 5;15(4):e1008009.
74. Dahl A, Nguyen K, Cai N, Gandal MJ, Flint J, Zaitlen N. A Robust Method Uncovers Significant Context-Specific Heritability in Diverse Complex Traits. *The American Journal of Human Genetics*. 2020 Jan 2;106(1):71–91.
75. Coleman JRI, on the behalf of Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Peyrot WJ, Purves KL, Davis KAS, Rayner C, et al. Genome-wide gene-environment analyses of major depressive disorder and reported lifetime traumatic experiences in UK Biobank. *Mol Psychiatry* [Internet]. 2020 Jan 23 [cited 2020 May 22]; Available from: <http://www.nature.com/articles/s41380-019-0546-6>
76. Peyrot WJ, Milaneschi Y, Abdellaoui A, Sullivan PF, Hottenga JJ, Boomsma DI, et al. Effect of polygenic risk scores on depression in childhood trauma. *Br J Psychiatry*. 2014 Aug;205(2):113–9.
77. Peyrot WJ, Van der Auwera S, Milaneschi Y, Dolan CV, Madden PAF, Sullivan PF, et al. Does Childhood Trauma Moderate Polygenic Risk for Depression? A Meta-analysis of 5765 Subjects From the Psychiatric Genomics Consortium. *Biological Psychiatry*. 2018 Jul;84(2):138–47.
78. Purcell S. Variance Components Models for Gene–Environment Interaction in Twin Analysis. *twin res*. 2002 Dec 1;5(6):554–71.

79. Moore R, BIOS Consortium, Casale FP, Jan Bonder M, Horta D, Franke L, et al. A linear mixed-model approach to study multivariate gene–environment interactions. *Nat Genet.* 2019 Jan;51(1):180–6.
80. Fried EI. Problematic assumptions have slowed down depression research: why symptoms, not syndromes are the way forward. *Front Psychol [Internet].* 2015 Mar 23 [cited 2020 May 31];6. Available from: <http://www.frontiersin.org/Psychopathology/10.3389/fpsyg.2015.00309/abstract>
81. Persons JB. The advantages of studying psychological phenomena rather than psychiatric diagnoses. *American Psychologist.* 1986;41(11):1252–60.
82. Thorp JG, Marees AT, Ong J-S, An J, MacGregor S, Derks EM. Genetic heterogeneity in self-reported depressive symptoms identified through genetic analyses of the PHQ-9. *Psychological Medicine.* undefined/ed;1–12.
83. Thorp JG, Campos AI, Grotzinger AD, Gerring Z, An J, Ong J-S, et al. Symptom-level genetic modelling identifies novel risk loci and unravels the shared genetic architecture of anxiety and depression [Internet]. *Genetic and Genomic Medicine;* 2020 Apr [cited 2020 Apr 22]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.04.08.20057653>
84. Dennis J, Sealock J, Levinson RT, Farber-Eger E, Franco J, Fong S, et al. Genetic risk for major depressive disorder and loneliness in sex-specific associations with coronary artery disease. *Molecular Psychiatry.* 2019 Dec 3;1–11.
85. Abdellaoui A, Sanchez-Roige S, Sealock J, Treur JL, Dennis J, Fontanillas P, et al. Phenome-wide investigation of health outcomes associated with genetic predisposition to loneliness. *Hum Mol Genet.* 2019 Nov 15;28(22):3853–65.
86. Arnau-Soler A, Macdonald-Dunlop E, Adams MJ, Clarke T-K, MacIntyre DJ, Milburn K, et al. Genome-wide by environment interaction studies of depressive symptoms and psychosocial stress in UK Biobank and Generation Scotland. *Translational Psychiatry.* 2019 Feb 4;9(1):1–13.
87. Xia CH, Ma Z, Ciric R, Gu S, Betzel RF, Kaczkurkin AN, et al. Linked dimensions of psychopathology and connectivity in functional brain networks. *Nature Communications.* 2018 Aug 1;9(1):1–14.
88. Smith SM, Nichols TE, Vidaurre D, Winkler AM, Behrens TEJ, Glasser MF, et al. A positive-negative mode of population covariation links brain connectivity, demographics and behavior. *Nature Neuroscience.* 2015 Nov;18(11):1565–7.
89. Zhang Y, Li M, Wang Q, Hsu JS, Deng W, Ma X, et al. A joint study of whole exome sequencing and structural MRI analysis in major depressive disorder. *Psychol Med.* 2020 Feb;50(3):384–95.
90. Arloth J, Eraslan G, Andlauer TFM, Martins J, Iurato S, Kühnel B, et al. DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning. *PLOS Computational Biology.* 2020 Feb 3;16(2):e1007616.
91. Li S, Li Y, Li X, Liu J, Huo Y, Wang J, et al. Regulatory mechanisms of major depressive disorder risk variants. *Mol Psychiatry [Internet].* 2020 Mar 25 [cited 2020 May 25]; Available from: <http://www.nature.com/articles/s41380-020-0715-7>



92. Gottesman II, Shields J. Genetic Theorizing and Schizophrenia. *The British Journal of Psychiatry*. 1973 Jan;122(566):15–30.
93. Flint J, Munafò MR. The endophenotype concept in psychiatric genetics. *Psychological Medicine*. 2007 Feb;37(2):163–80.
94. Sinnott-Armstrong N, Naqvi S, Rivas MA, Pritchard JK. GWAS of three molecular traits highlights core genes and pathways alongside a highly polygenic background. *bioRxiv*. 2020 Apr 22;2020.04.20.051631.
95. Sanchez-Roige S, Palmer AA. Emerging phenotyping strategies will advance our understanding of psychiatric genetics. *Nature Neuroscience*. 2020 Apr;23(4):475–80.
96. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005 Jun 1;62(6):617.
97. Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. *Science*. 2018 Feb 9;359(6376):693–7.
98. Consortium TB, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, et al. Analysis of shared heritability in common disorders of the brain. *Science* [Internet]. 2018 Jun 22 [cited 2020 Apr 21];360(6395). Available from: <https://science.sciencemag.org/content/360/6395/eaap8757>
99. Lee PH, Anttila V, Won H, Feng Y-CA, Rosenthal J, Zhu Z, et al. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell*. 2019 Dec 12;179(7):1469-1482.e11.
100. Turley P, Walters RK, Maghzian O, Okbay A, Lee JJ, Fontana MA, et al. Multi-trait analysis of genome-wide association summary statistics using MTAG. *Nature Genetics*. 2018 Feb;50(2):229–37.
101. Maier R, Moser G, Chen G-B, Ripke S, Absher D, Agartz I, et al. Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. *The American Journal of Human Genetics*. 2015 Feb 5;96(2):283–94.
102. Schork AJ, Won H, Appadurai V, Nudel R, Gandal M, Delaneau O, et al. A genome-wide association study of shared risk across psychiatric disorders implicates gene regulation during fetal neurodevelopment. *Nat Neurosci*. 2019 Mar;22(3):353–61.
103. Caspi A, Houts RM, Belsky DW, Goldman-Mellor SJ, Harrington H, Israel S, et al. The p Factor: One General Psychopathology Factor in the Structure of Psychiatric Disorders? *Clinical Psychological Science*. 2014 Mar;2(2):119–37.
104. Selzam S, Coleman JRI, Caspi A, Moffitt TE, Plomin R. A polygenic p factor for major psychiatric disorders. *Transl Psychiatry*. 2018 Dec;8(1):205.

105. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders. *AJP*. 2010 Jul 1;167(7):748–51.

UNCORRECTED MANUSCRIPT